Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Here’s What Happened

Posted by Anthony Miller on Feb 4th, 2026

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 101,624 shares traded hands during mid-day trading, a decline of 12% from the previous session’s volume of 115,176 shares.The stock last traded at $28.30 and had previously closed at $27.7950.

Analyst Upgrades and Downgrades

Separately, UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat, Chugai Pharmaceutical presently has a consensus rating of “Strong Buy”.

Read Our Latest Report on Chugai Pharmaceutical

Chugai Pharmaceutical Trading Up 1.3%

The business’s 50 day simple moving average is $26.86 and its two-hundred day simple moving average is $24.55. The firm has a market capitalization of $92.68 billion, a P/E ratio of 32.37 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.25 EPS for the quarter. The business had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.22%. Analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.